Artemis Antibody [H20J21]

Catalog No.: F1506

Application: Reactivity: Human, Monkey

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:200

Application
WB, IP

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Monkey

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
90 kDa

Datasheet & SDS

生物学的記述

Specificity
Artemis Antibody [H20J21] detects endogenous levels of total Artemis protein.

Clone
H20J21

Synonym(s)
Protein artemis; DNA cross-link repair 1C protein; Protein A-SCID; SNM1 homolog C; hSNM1C; SNM1-like protein; DCLRE1C; ARTEMIS; ASCID; SCIDA; SNM1C

Background
Artemis (DCLRE1C, also known as SNM1C) is a ubiquitously expressed nuclear nuclease belonging to the metallo-β-lactamase (MBL) superfamily, essential for non-homologous end-joining (NHEJ) DNA repair and V(D)J recombination in developing lymphocytes. Artemis is a 692-amino-acid protein with an N-terminal catalytic domain (residues 1-360) comprising a core MBL fold (α/β-β/α sandwich) and embedded β-CASP subdomain containing conserved motifs 1-4 (His33, His35, His115, Asp116 coordinating Zn²⁺ ions M1/M2) and motifs A-C for nucleic acid processing, plus a largely unstructured C-terminal regulatory tail (residues 361-692) that autoinhibits activity and mediates DNA-PKcs tethering. DNA-PKcs phosphorylates Artemis (e.g., at Thr127, Ser251) upon DSB recognition, activating its structure-specific endonuclease activity to open hairpin-sealed coding ends in V(D)J recombination, trim 5'/3' overhangs, flaps, and bubbles in NHEJ for XRCC4/LIG4 ligation, and process IR-induced complex ends while antagonizing HR via 53BP1-PTIP interaction. ATM/ATR further phosphorylate Artemis for G2/M and S-phase checkpoint recovery, promoting Cdk1-cyclin B activation and cyclin E degradation via SCF^{Fbw7}. Biallelic mutations cause radiosensitive severe combined immunodeficiency (RS-SCID) with defective V(D)J joining and genome instability predisposing to malignancy.

Background

Artemis (DCLRE1C, also known as SNM1C) is a ubiquitously expressed nuclear nuclease belonging to the metallo-β-lactamase (MBL) superfamily, essential for non-homologous end-joining (NHEJ) DNA repair and V(D)J recombination in developing lymphocytes. Artemis is a 692-amino-acid protein with an N-terminal catalytic domain (residues 1-360) comprising a core MBL fold (α/β-β/α sandwich) and embedded β-CASP subdomain containing conserved motifs 1-4 (His33, His35, His115, Asp116 coordinating Zn²⁺ ions M1/M2) and motifs A-C for nucleic acid processing, plus a largely unstructured C-terminal regulatory tail (residues 361-692) that autoinhibits activity and mediates DNA-PKcs tethering. DNA-PKcs phosphorylates Artemis (e.g., at Thr127, Ser251) upon DSB recognition, activating its structure-specific endonuclease activity to open hairpin-sealed coding ends in V(D)J recombination, trim 5'/3' overhangs, flaps, and bubbles in NHEJ for XRCC4/LIG4 ligation, and process IR-induced complex ends while antagonizing HR via 53BP1-PTIP interaction. ATM/ATR further phosphorylate Artemis for G2/M and S-phase checkpoint recovery, promoting Cdk1-cyclin B activation and cyclin E degradation via SCF^{Fbw7}. Biallelic mutations cause radiosensitive severe combined immunodeficiency (RS-SCID) with defective V(D)J joining and genome instability predisposing to malignancy.

References
[1] Poinsignon C, et al. J Exp Med. 2004 Feb 2;199(3):315-21. [2] Yosaatmadja Y, et al. Nucleic Acids Res. 2021 Sep 20;49(16):9310-9326.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%